✦ LIBER ✦

Inhibition of epidermal growth factor receptor activation by tyrosine kinase inhibitor enhances in vivo histamine stimulated gastric acid secretion in the rat

✍ Scribed by Ancha, Hari B.; Tedesco, Dustin S.; Ancha, Hanumantha R.; Harty, Richard F.

Book ID: 122018574
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 263 KB
Volume: 124
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(03)83085-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Transforming growth factor-α and epiderm

Transforming growth factor-α and epidermal growth factor inhibit gastric acid secretion and stimulate release of somatostatin and neurotensin in the conscious rat

✍ G. Grupcev; C. Wallin; S. Emås; E. Theodorsson; P.M. Hellström 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 580 KB

Genistein enhances the effect of epiderm

Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Antoinette Wozniak; Fazlul H. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 782 KB

Irreversible inhibition of epidermal gro

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

✍ Carolyn M. Discafani; Marion L. Carroll; M.Brawner Floyd Jr.; Irwin J. Hollander 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 358 KB

Retractions: 4,5-Dianilinophthalimide: A

Retractions: 4,5-Dianilinophthalimide: A Protein-Tyrosine Kinase Inhibitor with Selectivity for the Epidermal Growth Factor Receptor Signal Transduction Pathway and Potent in vivo Antitumor Activity; Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class

📂 Article 📅 1998 🏛 National Academy of Sciences 🌐 English ⚖ 238 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant